These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 21533509)
21. Human DNA-Topoisomerases - Diagnostic and Therapeutic Implications for Cancer. Kellner U; Rudolph P; Parwaresch R Onkologie; 2000 Oct; 23(5):424-430. PubMed ID: 11441236 [TBL] [Abstract][Full Text] [Related]
22. Topoisomerase II-alpha expression in different cell cycle phases in fresh human breast carcinomas. Villman K; Ståhl E; Liljegren G; Tidefelt U; Karlsson MG Mod Pathol; 2002 May; 15(5):486-91. PubMed ID: 12011253 [TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical staining for DNA topoisomerase I, DNA topoisomerase II-alpha and p53 in gastric carcinomas. Coleman LW; Bronstein IB; Holden JA Anticancer Res; 2001; 21(2A):1167-72. PubMed ID: 11396158 [TBL] [Abstract][Full Text] [Related]
24. Predictive value of topoisomerase II alpha immunostaining in urothelial bladder carcinoma. Nakopoulou L; Zervas A; Lazaris AC; Constantinides C; Stravodimos C; Davaris P; Dimopoulos C J Clin Pathol; 2001 Apr; 54(4):309-13. PubMed ID: 11304849 [TBL] [Abstract][Full Text] [Related]
25. Human DNA topoisomerase I: An anticancer drug target present in human sarcomas. Coleman LW; Rohr LR; Bronstein IB; Holden JA Hum Pathol; 2002 Jun; 33(6):599-607. PubMed ID: 12152158 [TBL] [Abstract][Full Text] [Related]
26. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide. Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806 [TBL] [Abstract][Full Text] [Related]
27. Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma. Shi H; Lu D; Shu Y; Shi W; Lu S; Wang K Cancer Invest; 2008 May; 26(4):344-51. PubMed ID: 18443954 [TBL] [Abstract][Full Text] [Related]
28. Correlation between Topo II alpha expression and chemosensitivity testing for Topo II-targeting drugs in gynaecological carcinomas. Koshiyama M; Fujii H; Kinezaki M; Yoshida M Anticancer Res; 2001; 21(2A):905-10. PubMed ID: 11396183 [TBL] [Abstract][Full Text] [Related]
29. Selective use of an alternative stop codon and polyadenylation signal within intron sequences leads to a truncated topoisomerase II alpha messenger RNA and protein in human HL-60 leukemia cells selected for resistance to mitoxantrone. Harker WG; Slade DL; Parr RL; Holguin MH Cancer Res; 1995 Nov; 55(21):4962-71. PubMed ID: 7585537 [TBL] [Abstract][Full Text] [Related]
30. Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme. Chen M; Beck WT Cancer Res; 1993 Dec; 53(24):5946-53. PubMed ID: 8261408 [TBL] [Abstract][Full Text] [Related]
31. Enhanced expression of DNA topoisomerase II genes in human medulloblastoma and its possible association with etoposide sensitivity. Uesaka T; Shono T; Kuga D; Suzuki SO; Niiro H; Miyamoto K; Matsumoto K; Mizoguchi M; Ohta M; Iwaki T; Sasaki T J Neurooncol; 2007 Sep; 84(2):119-29. PubMed ID: 17361331 [TBL] [Abstract][Full Text] [Related]
32. Expression and relationship between topoisomerase I and II alpha genes in tumor and normal tissues in esophageal, gastric and colon cancers. Kim R; Ohi Y; Inoue H; Toge T Anticancer Res; 1999; 19(6B):5393-8. PubMed ID: 10697567 [TBL] [Abstract][Full Text] [Related]
33. P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. van der Zee AG; Hollema H; de Jong S; Boonstra H; Gouw A; Willemse PH; Zijlstra JG; de Vries EG Cancer Res; 1991 Nov; 51(21):5915-20. PubMed ID: 1682037 [TBL] [Abstract][Full Text] [Related]
34. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment. Chen S; Gomez SP; McCarley D; Mainwaring MG Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828 [TBL] [Abstract][Full Text] [Related]
35. Expression of multidrug resistance-related proteins p-glycoprotein, glutathione-s-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma. Shi H; Lu D; Shu Y; Shi W; Lu S; Wang K Hepatogastroenterology; 2008; 55(86-87):1530-6. PubMed ID: 19102336 [TBL] [Abstract][Full Text] [Related]
36. Correlation between topoisomerase-IIalpha gene amplification and protein expression in HER-2 amplified breast cancer. Durbecq V; Desmed C; Paesmans M; Cardoso F; Di Leo A; Mano M; Rouas G; Leroy JY; Sotiriou C; Piccart M; Larsimont D Int J Oncol; 2004 Nov; 25(5):1473-9. PubMed ID: 15492841 [TBL] [Abstract][Full Text] [Related]
37. The association between the p53/topoisomerase I and p53/ topoisomerase IIalpha immunophenotypes and the progression of ovarian carcinomas. Bar JK; Grelewski P; Noga L; Rabczyński J; Gryboś M; Jeleń M Adv Clin Exp Med; 2012; 21(1):35-42. PubMed ID: 23214297 [TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas. Koshiyama M; Fujii H; Kinezaki M; Morita Y; Nanno H; Yoshida M Anticancer Res; 2001; 21(4B):2925-32. PubMed ID: 11712788 [TBL] [Abstract][Full Text] [Related]
39. Drastic reduction of topoisomerase II alpha associated with major acquired resistance to topoisomerase II active agents but minor perturbations of cell growth. Hashimoto S; Chatterjee S; Ranjit GB; Bao C; Ford J; Ganapathi R; Berger SJ; Berger NA Oncol Res; 1995; 7(7-8):407-16. PubMed ID: 8747604 [TBL] [Abstract][Full Text] [Related]
40. Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer. Cardoso F; Durbecq V; Larsimont D; Paesmans M; Leroy JY; Rouas G; Sotiriou C; Renard N; Richard V; Piccart MJ; Di Leo A Int J Oncol; 2004 Jan; 24(1):201-9. PubMed ID: 14654958 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]